1525 O'Brien Drive
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
CEO: Bob Ragusa
84 articles with GRAIL, LLC
GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation
Proprietary Methylation Technology Selected for Continued Development of Multi-Cancer Test
Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...
Company Also Announced Promotion of Alex Aravanis to Chief Scientific Officer
GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection
SUMMIT Study Partners Include UCL and University College London Hospitals NHS Foundation Trust in the United Kingdom, and Lung Cancer Alliance
Johnson & Johnson’s JLABS incubator in San Francisco recently convened a meeting of biopharma industry executives. One of the hot topics for one of the panels was the competition for talent.
GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at the European Society for Medical Oncology (ESMO) 2018 Congress
GRAIL, Inc. today announced that new data from the Circulating Cell-free Genome Atlas (CCGA) study will be presented by Minetta Liu, MD, Research Chair and Professor, Department of Oncology, Mayo Clinic, in an oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress taking place October 19 – 23 in Munich, Germany.
10/5/2018Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Renée Galá as Chief Financial Officer, effective January 3, 2019.
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
8/13/2018GSK's Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let's take a look at some of those!
GRAIL, Inc. announced the appointment of Hal Barron, MD, and Hans Bishop to its Board of Directors.
San Francisco-based Mammoth Biosciences, co-founded by one of the originators of CRISPR gene editing, Jennifer Doudna, closed on a $23 million Series A financing round.
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products
George Golumbeski Appointed as President
Strategic partnership will focus on generating methylation data as part of ongoing research for early cancer detection
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
GRAIL, Inc. announced new data from the Circulating Cell-free Genome Atlas (CCGA) study.
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Grail announced a $300 million C financing. Since early 2016, Grail has raised over $1.5 billion.
With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.